Email this article EVALUATION OF THE CLINICAL AND ECONOMIC EFFECTIVENESS OF INTERFERON-GAMMA IN THE TREATMENT OF TUBERCULOSIS
- Authors: Plavinskiy S.L1, Shabalkin P.I.2
-
Affiliations:
- I.I. Mechnikov North-Western State Medical University
- N.N. Blokhin National Medical Cancer Research Center
- Issue: Vol 22, No 6 (2017)
- Pages: 276-280
- Section: Articles
- URL: https://journal-vniispk.ru/1560-9529/article/view/40981
- DOI: https://doi.org/10.17816/EID40981
- ID: 40981
Cite item
Full Text
Abstract
Tuberculosis worldwide is a serious problem for the health system and for society. Despite the fact that in recent years there has been a tendency to the decline in the incidence of tuberculosis, it remains to be one of the socially significant infections in the Russian Federation. Significant difficulties in the treatment of tuberculosis include the overcoming of the drug resistance of mycobacteria to the existing therapy, as well as the available limitations of the resources of the healthcare system in the Russian Federation. In this regard, there is a need to find additional opportunities to improve the effectiveness of the treatment and clinical and economic evaluation of existing treatment regimens. Interferon-gamma is an effective preparation for the management of tuberculosis. As a result of the pharmacoeconomic analysis, the administration of interferon-gamma (Ingaron) contributed to an increase in the quality of life by 2.1 QALY, and in terms of an addition to the therapy will be accompanied by savings of the budget of the Russian Federation up to 284 million rubles, or up to 27.3% of funds for the treatment of patients from this group.
Full Text
##article.viewOnOriginalSite##About the authors
S. L Plavinskiy
I.I. Mechnikov North-Western State Medical University
Author for correspondence.
Email: s.plavinskij@gmail.com
доктор мед. наук, начальник учебного управления ФГБОУ ВО СЗГМУ им. И.И. Мечникова Минздрава России
41, Kirochnaya Str. Saint-Petersburg, 191015, Russian Federation, Saint-Petersburg, RussiaPavel I. Shabalkin
N.N. Blokhin National Medical Cancer Research Center
Email: p.shabalkin@gmail.com
MD, PhD, N.N Blokhin National Medical Cancer Research Center, 24, Kashirskoe shosse, Moscow, 115478, Russia
24, Kashirskoe shosse, Moscow, 115478, RussiaReferences
- Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2016 году». М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2017 cтр. 88-90.
- Gao X.F., Yang Z.-W., Li J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. International Journal of Infectious Diseases. 15 (2011) e594-e600.
- Маркелов Ю.М., Кононенко Ю.С., Войшнис М.Р., Доева Л.В. Сравнительная оценка клинико-экономической эффективности лечения больных туберкулезом в условиях стационара и использования стационарзамещающих технологий. Туберкулез и болезни легких. 2015; 2: 32-8.
- Коломиец В.М., Дрёмова Н.Б., Рублёва Н.В. Фармакоэкономический анализ эффективности основного курса лечения туберкулеза в условиях стационара. Курский научно-практический вестник «Человек и его здоровье». 2011; (1): 45-50.
- Росстат. Здравоохранение в России. 2015; Стат. сб. М.; Росстат, 2015.
- Wolfson L.J., Walker A., Hettle R. et al. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS ONE. 2015; 10(3): P. e0120763.
- Filipovic-Pierucci A., Zarca K., Durand-Zaleski I. Markov models for health economic evaluation: The r package heemod. ArXiv e-prints. 2017. R package version 0.9.1. 1702.03252.
Supplementary files
